Loading…
Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film
Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in...
Saved in:
Published in: | BMC ophthalmology 2021-09, Vol.21 (1), p.1-319, Article 319 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343 |
---|---|
cites | cdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343 |
container_end_page | 319 |
container_issue | 1 |
container_start_page | 1 |
container_title | BMC ophthalmology |
container_volume | 21 |
creator | Sedlak, Lech Świerczyńska, Marta Borymska, Weronika Zych, Maria Wyględowska-Promieńska, Dorota |
description | Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma |
doi_str_mv | 10.1186/s12886-021-02079-y |
format | article |
fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2e8f1c01b5144616863c1673200b117b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A675229311</galeid><doaj_id>oai_doaj_org_article_2e8f1c01b5144616863c1673200b117b</doaj_id><sourcerecordid>A675229311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</originalsourceid><addsrcrecordid>eNp1kktv1DAQxyMEoqXwBThF4sKBFI_j2N4LUlXxWKkSFzhbfky23ib2YmdXbL8L3xWnW5UuAlmWLc9v_vPwVNVrIOcAkr_PQKXkDaFQNhGLZv-kOgUmoKEMuqeP7ifVi5zXpFCslc-rk5YxQTghp9Wv5bjRdqpjX7uYbuOgR-_wXW0w3OrhJga_HZtNwoxph-4xU-vg_oeZ5MMDF0OdcUA7zQYfR51uMOU5YvzpnZ78Dus8Fd9c-1BP11hPqFPd-2F8WT3r9ZDx1f15Vn3_9PHb5Zfm6uvn5eXFVWM7RqbGCWE6MMDROGmZkVb0hPJu4bS2VHCtJaXoDErHCNUdlw5NC2ApLLRpWXtWLQ-6Luq12iRfktyrqL26e4hppXSavB1QUZQ9WAIlIGMcuOStBS5aSogBEKZofThobbZmRGcxTEkPR6LHluCv1SrulGQAXUeKwNt7gRR_bDFPavTZ4jDogHGbFS35dwvOYUbf_IWu4zaF0qpCCcY7yjj_Q610KcCHPpa4dhZVF1x0lC5KLwp1_g-qLIejtzFg-RA8dqAHB5tizgn7hxqBqHlA1WFAVRlQdTegat_-Bob12kA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574652466</pqid></control><display><type>article</type><title>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</title><source>ProQuest - Publicly Available Content Database</source><source>PubMed Central</source><creator>Sedlak, Lech ; Świerczyńska, Marta ; Borymska, Weronika ; Zych, Maria ; Wyględowska-Promieńska, Dorota</creator><creatorcontrib>Sedlak, Lech ; Świerczyńska, Marta ; Borymska, Weronika ; Zych, Maria ; Wyględowska-Promieńska, Dorota</creatorcontrib><description>Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma</description><identifier>ISSN: 1471-2415</identifier><identifier>EISSN: 1471-2415</identifier><identifier>DOI: 10.1186/s12886-021-02079-y</identifier><identifier>PMID: 34470600</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Acids ; Age ; Analysis ; Antioxidants ; Benzalkonium chloride ; Biological markers ; Biomarkers ; Brinzolamide ; Carbonic anhydrase inhibitor ; Carbonic anhydrases ; Catalase ; Cornea ; Disease ; Dorzolamide ; Glaucoma ; Glutathione peroxidase ; Ocular surface ; Ophthalmology ; Oxidants ; Oxidative stress ; Pharmaceutical industry ; Preservatives ; Reagents ; Sulfhydryl groups ; Superoxide ; Superoxide dismutase ; Surface active agents</subject><ispartof>BMC ophthalmology, 2021-09, Vol.21 (1), p.1-319, Article 319</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</citedby><cites>FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411550/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2574652466?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids></links><search><creatorcontrib>Sedlak, Lech</creatorcontrib><creatorcontrib>Świerczyńska, Marta</creatorcontrib><creatorcontrib>Borymska, Weronika</creatorcontrib><creatorcontrib>Zych, Maria</creatorcontrib><creatorcontrib>Wyględowska-Promieńska, Dorota</creatorcontrib><title>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</title><title>BMC ophthalmology</title><description>Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma</description><subject>Acids</subject><subject>Age</subject><subject>Analysis</subject><subject>Antioxidants</subject><subject>Benzalkonium chloride</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Brinzolamide</subject><subject>Carbonic anhydrase inhibitor</subject><subject>Carbonic anhydrases</subject><subject>Catalase</subject><subject>Cornea</subject><subject>Disease</subject><subject>Dorzolamide</subject><subject>Glaucoma</subject><subject>Glutathione peroxidase</subject><subject>Ocular surface</subject><subject>Ophthalmology</subject><subject>Oxidants</subject><subject>Oxidative stress</subject><subject>Pharmaceutical industry</subject><subject>Preservatives</subject><subject>Reagents</subject><subject>Sulfhydryl groups</subject><subject>Superoxide</subject><subject>Superoxide dismutase</subject><subject>Surface active agents</subject><issn>1471-2415</issn><issn>1471-2415</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1kktv1DAQxyMEoqXwBThF4sKBFI_j2N4LUlXxWKkSFzhbfky23ib2YmdXbL8L3xWnW5UuAlmWLc9v_vPwVNVrIOcAkr_PQKXkDaFQNhGLZv-kOgUmoKEMuqeP7ifVi5zXpFCslc-rk5YxQTghp9Wv5bjRdqpjX7uYbuOgR-_wXW0w3OrhJga_HZtNwoxph-4xU-vg_oeZ5MMDF0OdcUA7zQYfR51uMOU5YvzpnZ78Dus8Fd9c-1BP11hPqFPd-2F8WT3r9ZDx1f15Vn3_9PHb5Zfm6uvn5eXFVWM7RqbGCWE6MMDROGmZkVb0hPJu4bS2VHCtJaXoDErHCNUdlw5NC2ApLLRpWXtWLQ-6Luq12iRfktyrqL26e4hppXSavB1QUZQ9WAIlIGMcuOStBS5aSogBEKZofThobbZmRGcxTEkPR6LHluCv1SrulGQAXUeKwNt7gRR_bDFPavTZ4jDogHGbFS35dwvOYUbf_IWu4zaF0qpCCcY7yjj_Q610KcCHPpa4dhZVF1x0lC5KLwp1_g-qLIejtzFg-RA8dqAHB5tizgn7hxqBqHlA1WFAVRlQdTegat_-Bob12kA</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Sedlak, Lech</creator><creator>Świerczyńska, Marta</creator><creator>Borymska, Weronika</creator><creator>Zych, Maria</creator><creator>Wyględowska-Promieńska, Dorota</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20210901</creationdate><title>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</title><author>Sedlak, Lech ; Świerczyńska, Marta ; Borymska, Weronika ; Zych, Maria ; Wyględowska-Promieńska, Dorota</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acids</topic><topic>Age</topic><topic>Analysis</topic><topic>Antioxidants</topic><topic>Benzalkonium chloride</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Brinzolamide</topic><topic>Carbonic anhydrase inhibitor</topic><topic>Carbonic anhydrases</topic><topic>Catalase</topic><topic>Cornea</topic><topic>Disease</topic><topic>Dorzolamide</topic><topic>Glaucoma</topic><topic>Glutathione peroxidase</topic><topic>Ocular surface</topic><topic>Ophthalmology</topic><topic>Oxidants</topic><topic>Oxidative stress</topic><topic>Pharmaceutical industry</topic><topic>Preservatives</topic><topic>Reagents</topic><topic>Sulfhydryl groups</topic><topic>Superoxide</topic><topic>Superoxide dismutase</topic><topic>Surface active agents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sedlak, Lech</creatorcontrib><creatorcontrib>Świerczyńska, Marta</creatorcontrib><creatorcontrib>Borymska, Weronika</creatorcontrib><creatorcontrib>Zych, Maria</creatorcontrib><creatorcontrib>Wyględowska-Promieńska, Dorota</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sedlak, Lech</au><au>Świerczyńska, Marta</au><au>Borymska, Weronika</au><au>Zych, Maria</au><au>Wyględowska-Promieńska, Dorota</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film</atitle><jtitle>BMC ophthalmology</jtitle><date>2021-09-01</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>1</spage><epage>319</epage><pages>1-319</pages><artnum>319</artnum><issn>1471-2415</issn><eissn>1471-2415</eissn><abstract>Background Long-term use of topical, especially benzalkonium chloride (BAC)-preserved, antiglaucoma medications can cause a negative impact on the ocular surface. The aim of the study was to assess the effect of topical carbonic anhydrase inhibitors (CAIs) on selected oxidative stress biomarkers in the tear film. Methods The patients were divided into four sex-matched groups: group C (n = 25) - control group - subjects who did not use topical antiglaucoma medications, group DL (n = 14) - patients using preservative-free dorzolamide, group DL + BAC (n = 16) - patients using topical BAC-preserved dorzolamide, group BL + BAC (n = 17) - patients using BAC-preserved brinzolamide. Subjects in all the study groups have been using the eye drops two times daily for 6-12 months. The oxidative stress biomarkers in the tear film samples were measured: total protein (TP) concentration, advanced oxidation protein products (AOPP) content, total sulfhydryl (-SH) groups content, the activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as Total Oxidant Status (TOS), Total Antioxidant Response (TAR), and Oxidative Stress Index (OSI). Results The advanced oxidation protein products content, Total Oxidant Status as well as superoxide dismutase and catalase activities in the group DL + BAC and BL + BAC were higher in comparison with the group C. The total sulfhydryl groups content was lower in the group DL + BAC and BL + BAC when compared to group C. Oxidative Stress Index was higher in the groups DL + BAC and BL + BAC in comparison with the groups DL and C. Conclusions Use of topical benzalkonium chloride-preserved carbonic anhydrase inhibitors increases oxidative stress in the tear film. Keywords: Benzalkonium chloride, Dorzolamide, Brinzolamide, Carbonic anhydrase inhibitor, Oxidative stress, Ocular surface, Glaucoma</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><pmid>34470600</pmid><doi>10.1186/s12886-021-02079-y</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1471-2415 |
ispartof | BMC ophthalmology, 2021-09, Vol.21 (1), p.1-319, Article 319 |
issn | 1471-2415 1471-2415 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_2e8f1c01b5144616863c1673200b117b |
source | ProQuest - Publicly Available Content Database; PubMed Central |
subjects | Acids Age Analysis Antioxidants Benzalkonium chloride Biological markers Biomarkers Brinzolamide Carbonic anhydrase inhibitor Carbonic anhydrases Catalase Cornea Disease Dorzolamide Glaucoma Glutathione peroxidase Ocular surface Ophthalmology Oxidants Oxidative stress Pharmaceutical industry Preservatives Reagents Sulfhydryl groups Superoxide Superoxide dismutase Surface active agents |
title | Impact of dorzolamide, benzalkonium-preserved dorzolamide and benzalkonium-preserved brinzolamide on selected biomarkers of oxidative stress in the tear film |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T07%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20dorzolamide,%20benzalkonium-preserved%20dorzolamide%20and%20benzalkonium-preserved%20brinzolamide%20on%20selected%20biomarkers%20of%20oxidative%20stress%20in%20the%20tear%20film&rft.jtitle=BMC%20ophthalmology&rft.au=Sedlak,%20Lech&rft.date=2021-09-01&rft.volume=21&rft.issue=1&rft.spage=1&rft.epage=319&rft.pages=1-319&rft.artnum=319&rft.issn=1471-2415&rft.eissn=1471-2415&rft_id=info:doi/10.1186/s12886-021-02079-y&rft_dat=%3Cgale_doaj_%3EA675229311%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-d77b51b16ebd8c4b8c7f02659daac276aa822edbe8d402a568deb311c219ab343%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2574652466&rft_id=info:pmid/34470600&rft_galeid=A675229311&rfr_iscdi=true |